NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
The study will evaluate changes in the Quantitative Myasthenia Gravis Total Score and the Myasthenia Gravis Activities of Living, among other endpoints and take place across both US and European clinical sites.
- The study will evaluate changes in the Quantitative Myasthenia Gravis Total Score and the Myasthenia Gravis Activities of Living, among other endpoints and take place across both US and European clinical sites.
- Jorge A. Quiroz, EVP, Chief Medical Officer of NMD Pharma, commented: “Generalized myasthenia gravis is a rare disorder characterized by neuromuscular transmission dysfunction that leads to severe and fluctuating muscle weakness and fatigue.
- While new and approved therapies address the autoimmune response, many patients with myasthenia gravis have persistent symptomatology.
- Generalized myasthenia gravis patients who are AChR or MuSK antibody positive in the US and Europe are encouraged to participate in the study.